Erudio Healtherudio.com
Congress · May 29 – Jun 2, 2026 · past meeting
2026 ASCO Annual Meeting
Trials whose public commentary places their results at 2026 ASCO Annual Meeting, May 29 – Jun 2, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
85 trials: 8 with reports and 77 with no report yet. Organised by American Society of Clinical Oncology (ASCO); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
Published reports · 8
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Advanced solid tumors · 1 | |||||||
| M21-404 telisotuzumab adizutecan (ABBV-400); telisotuzumab adizutecan (ABBV-400) plus bevacizumab placed at 2026 ASCO Annual Meeting by 2 sources NCT05029882 · AbbVie | advanced solid tumors | Phase 1 | 152 | 61 | Standard | Nov 2, 2026 | Preview |
| AL amyloidosis · 1 | |||||||
| LINKER-AL2 linvoseltamab placed at 2026 ASCO Annual Meeting by 11 sources NCT06292780 · Regeneron Pharmaceuticals | relapsed or refractory systemic light chain amyloidosis | Phase 1/Phase 2 | 149 | 25 | Focused | Nov 1, 2026 | Preview |
| Breast cancer · 1 | |||||||
| PANKU-Breast02 izalontamab brengitecan (BL-B01D1) placed at 2026 ASCO Annual Meeting by 9 sources NCT06382142 · Sichuan Baili Pharmaceutical Co., Ltd. | unresectable locally advanced or metastatic triple-negative breast cancer | Phase 3 | 125 | 28 | Focused | Nov 1, 2026 | Preview |
| Non-small cell lung cancer · 4 | |||||||
| AcceleRET-Lung pralsetinib placed at 2026 ASCO Annual Meeting by 15 sources NCT04222972 · Hoffmann-La Roche | first-line RET fusion-positive metastatic non-small cell lung cancer | Phase 3 | 63 | 24 | Focused | Nov 1, 2026 | Preview |
| ROSETTA Lung-02 pumitamig (BNT327) placed at 2026 ASCO Annual Meeting by 14 sources NCT06712316 · BioNTech SE | first-line non-small cell lung cancer | Phase 2/Phase 3 | 146 | 31 | Focused | Nov 2, 2026 | Preview |
| SOLARA BH-30643; BH-30643 plus carboplatin plus pemetrexed placed at 2026 ASCO Annual Meeting by 5 sources NCT06706076 · BlossomHill Therapeutics | EGFR- or HER2-mutated advanced NSCLC | Phase 1/Phase 2 | 71 | 23 | Focused | Oct 29, 2026 | Preview |
| HARMONi-3 ivonescimab placed at 2026 ASCO Annual Meeting by 2 sources NCT05899608 · Summit Therapeutics | first-line metastatic non-small cell lung cancer | Phase 3 | 286 | 97 | Standard | Nov 4, 2026 | Preview |
| Prostate cancer · 1 | |||||||
| LIBERTAS apalutamide placed at 2026 ASCO Annual Meeting by 2 sources NCT05884398 · Janssen Research & Development, LLC | metastatic castration-sensitive prostate cancer | Phase 3 | 813 | 56 | Deep | Nov 3, 2026 | Preview |
No report yet · 77
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Advanced solid tumors · 2 | |||||||
| ALKOVE-1 neladalkib (NVL-655) placed at 2026 ASCO Annual Meeting by 10 sources NCT05384626 · Nuvalent Inc. DeepView → | advanced solid tumors harboring ALK rearrangement or mutation | Phase 1/Phase 2 | Deep | View | |||
| LOXO-RAS-20001 olomorasib (LY3537982); olomorasib (LY3537982) plus pembrolizumab; olomorasib (LY3537982) plus cetuximab placed at 2026 ASCO Annual Meeting by 2 sources NCT04956640 · Eli Lilly and Company DeepView → | KRAS G12C-mutant advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| Biliary tract cancer · 1 | |||||||
| FIGHT-302 pemigatinib placed at 2026 ASCO Annual Meeting by 14 sources NCT03656536 · Incyte Corporation DeepView → | first-line advanced cholangiocarcinoma with FGFR2 rearrangements | Phase 3 | Deep | View | |||
| Breast cancer · 16 | |||||||
| SERENA-6 camizestrant plus palbociclib; camizestrant plus abemaciclib; camizestrant plus ribociclib placed at 2026 ASCO Annual Meeting by 17 sources NCT04964934 · AstraZeneca DeepView → | ESR1-mutated ER-positive HER2-negative metastatic breast cancer | Phase 3 | Deep | View | |||
| ASCENT-03 sacituzumab govitecan placed at 2026 ASCO Annual Meeting by 13 sources NCT05382299 · Gilead Sciences DeepView → | previously untreated advanced triple-negative breast cancer | Phase 3 | Deep | View | |||
| ASCENT-04 sacituzumab govitecan plus pembrolizumab placed at 2026 ASCO Annual Meeting by 13 sources NCT05382286 · Gilead Sciences DeepView → | PD-L1-positive previously untreated advanced triple-negative breast cancer | Phase 3 | Deep | View | |||
| VIKTORIA-1 gedatolisib plus palbociclib plus fulvestrant; gedatolisib plus fulvestrant placed at 2026 ASCO Annual Meeting by 12 sources NCT05501886 · Celcuity Inc DeepView → | HR+/HER2- advanced breast cancer after CDK4/6 inhibitor therapy | Phase 3 | Deep | View | |||
| NATALEE ribociclib placed at 2026 ASCO Annual Meeting by 10 sources NCT03701334 · Novartis Pharmaceuticals DeepView → | HR+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| HER2CLIMB-05 tucatinib plus trastuzumab plus pertuzumab placed at 2026 ASCO Annual Meeting by 7 sources NCT05132582 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | HER2+ metastatic breast cancer (first-line maintenance) | Phase 3 | Deep | View | |||
| TROPION-Breast02 datopotamab deruxtecan placed at 2026 ASCO Annual Meeting by 6 sources NCT05374512 · AstraZeneca DeepView → | first-line inoperable or metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| BWEL Tests a strategy, not a drug placed at 2026 ASCO Annual Meeting by 4 sources NCT02750826 · Alliance for Clinical Trials in Oncology DeepView → | overweight and obese women with early breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast05 trastuzumab deruxtecan placed at 2026 ASCO Annual Meeting by 4 sources NCT04622319 · Daiichi Sankyo DeepView → | HER2-positive residual invasive breast cancer following neoadjuvant therapy | Phase 3 | Deep | View | |||
| evERA giredestrant plus everolimus placed at 2026 ASCO Annual Meeting by 4 sources NCT05306340 · Genentech, Inc. DeepView → | ER-positive, HER2-negative locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| Neo-Healer anbenitamab plus HB1801 placed at 2026 ASCO Annual Meeting by 4 sources NCT06747338 · Shanghai JMT-Bio Inc. FocusedView → | early or locally advanced HER2-positive breast cancer | Phase 3 | Focused | View | |||
| OASIS-4 Drug not named yet placed at 2026 ASCO Annual Meeting by 4 sources NCT05587296 · Bayer DeepView → | vasomotor symptoms from endocrine therapy for breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast07 trastuzumab deruxtecan plus durvalumab; trastuzumab deruxtecan plus pertuzumab; trastuzumab deruxtecan plus paclitaxel placed at 2026 ASCO Annual Meeting by 3 sources NCT04538742 · AstraZeneca DeepView → | HER2-positive metastatic breast cancer | Phase 1/Phase 2 | Deep | View | |||
| KEYNOTE-522 pembrolizumab placed at 2026 ASCO Annual Meeting by 3 sources NCT03036488 · Merck Sharp & Dohme LLC DeepView → | high-risk early-stage triple-negative breast cancer | Phase 3 | Deep | View | |||
| PlanB docetaxel plus cyclophosphamide placed at 2026 ASCO Annual Meeting by 2 sources NCT01049425 · Women's Cancer Study Group GmbH DeepView → | HER2-negative early breast cancer | Phase 3 | Deep | View | |||
| TAILORx Drug not named yet placed at 2026 ASCO Annual Meeting by 2 sources NCT00310180 · National Cancer Institute (NCI) DeepView → | hormone receptor-positive HER2-negative node-negative breast cancer | Phase 3 | Deep | View | |||
| Colorectal cancer · 2 | |||||||
| BREAKWATER encorafenib plus cetuximab plus mFOLFOX6; encorafenib plus cetuximab placed at 2026 ASCO Annual Meeting by 10 sources NCT04607421 · Pfizer DeepView → | first-line BRAF V600E-mutant metastatic colorectal cancer | Phase 3 | Deep | View | |||
| CodeBreaK 300 sotorasib plus panitumumab placed at 2026 ASCO Annual Meeting by 2 sources NCT05198934 · Amgen DeepView → | KRAS G12C-mutated chemorefractory metastatic colorectal cancer | Phase 3 | Deep | View | |||
| Diffuse large B-cell lymphoma · 1 | |||||||
| SUNMO mosunetuzumab plus polatuzumab vedotin placed at 2026 ASCO Annual Meeting by 2 sources NCT05171647 · Hoffmann-La Roche DeepView → | transplant-ineligible relapsed/refractory large B-cell lymphoma | Phase 3 | Deep | View | |||
| Endometrial cancer · 2 | |||||||
| RUBY dostarlimab; dostarlimab plus niraparib placed at 2026 ASCO Annual Meeting by 4 sources NCT03981796 · Tesaro, Inc. DeepView → | primary advanced or recurrent endometrial cancer | Phase 3 | Deep | View | |||
| NRG-GY018 pembrolizumab placed at 2026 ASCO Annual Meeting by 3 sources NCT03914612 · National Cancer Institute (NCI) DeepView → | stage III-IV or recurrent endometrial cancer | Phase 3 | Deep | View | |||
| Gastroesophageal adenocarcinoma · 1 | |||||||
| HERIZON-GEA-01 zanidatamab; zanidatamab plus tislelizumab placed at 2026 ASCO Annual Meeting by 8 sources NCT05152147 · Jazz Pharmaceuticals DeepView → | HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma | Phase 3 | Deep | View | |||
| Head and neck squamous cell carcinoma · 1 | |||||||
| OrigAMI-4 amivantamab; amivantamab plus pembrolizumab; amivantamab plus paclitaxel placed at 2026 ASCO Annual Meeting by 3 sources NCT06385080 · Janssen Research & Development, LLC DeepView → | head and neck squamous cell carcinoma | Phase 1/Phase 2 | Deep | View | |||
| Hepatocellular carcinoma · 2 | |||||||
| EMERALD-3 durvalumab plus tremelimumab plus lenvatinib; durvalumab plus tremelimumab placed at 2026 ASCO Annual Meeting by 23 sources NCT05301842 · AstraZeneca DeepView → | locoregional hepatocellular carcinoma | Phase 3 | Deep | View | |||
| IMbrave251 atezolizumab plus lenvatinib; atezolizumab plus sorafenib placed at 2026 ASCO Annual Meeting by 7 sources NCT04770896 · Hoffmann-La Roche DeepView → | hepatocellular carcinoma previously treated with atezolizumab and bevacizumab | Phase 3 | Deep | View | |||
| Melanoma · 1 | |||||||
| KEYNOTE-942 intismeran autogene (mRNA-4157) plus pembrolizumab placed at 2026 ASCO Annual Meeting by 7 sources NCT03897881 · ModernaTX, Inc. DeepView → | high-risk resected melanoma | Phase 2 | Deep | View | |||
| Multiple myeloma · 4 | |||||||
| MajesTEC-9 teclistamab placed at 2026 ASCO Annual Meeting by 16 sources NCT05572515 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| SUCCESSOR-2 mezigdomide placed at 2026 ASCO Annual Meeting by 8 sources NCT05552976 · Bristol-Myers Squibb DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| inMMyCAR KLN-1010 placed at 2026 ASCO Annual Meeting by 3 sources NCT07075185 · Kelonia Therapeutics, Inc. DeepView → | relapsed and refractory multiple myeloma | Phase 1 | Deep | View | |||
| DREAMM-9 belantamab mafodotin plus bortezomib plus lenalidomide plus dexamethasone placed at 2026 ASCO Annual Meeting by 2 sources NCT04091126 · GlaxoSmithKline DeepView → | newly diagnosed multiple myeloma | Phase 1 | Deep | View | |||
| Non-small cell lung cancer · 12 | |||||||
| HARMONi-6 ivonescimab placed at 2026 ASCO Annual Meeting by 45 sources NCT05840016 · Akeso DeepView → | first-line advanced squamous non-small cell lung cancer | Phase 3 | Deep | View | |||
| LIBRETTO-432 selpercatinib placed at 2026 ASCO Annual Meeting by 40 sources NCT04819100 · Eli Lilly and Company DeepView → | stage IB-IIIA RET fusion-positive NSCLC | Phase 3 | Deep | View | |||
| OptiTROP-Lung05 sacituzumab tirumotecan plus pembrolizumab placed at 2026 ASCO Annual Meeting by 20 sources NCT06448312 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. DeepView → | first-line PD-L1-positive advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| WU-KONG28 sunvozertinib placed at 2026 ASCO Annual Meeting by 14 sources NCT05668988 · Dizal Pharmaceuticals DeepView → | first-line EGFR exon 20 insertion-mutated advanced NSCLC | Phase 3 | Deep | View | |||
| LORIN lorlatinib placed at 2026 ASCO Annual Meeting by 13 sources NCT05740943 · Guangdong Provincial People's Hospital DeepView → | ALK fusion stage III non-small cell lung cancer | Phase 2 | Deep | View | |||
| Krascendo-170 divarasib plus pembrolizumab; divarasib plus pembrolizumab plus platinum-based chemotherapy plus pemetrexed; divarasib placed at 2026 ASCO Annual Meeting by 10 sources NCT05789082 · Hoffmann-La Roche DeepView → | untreated KRAS G12C+ advanced non-small cell lung cancer | Phase 1/Phase 2 | Deep | View | |||
| CHRYSALIS-2 amivantamab plus lazertinib; lazertinib; amivantamab plus lazertinib plus carboplatin plus pemetrexed placed at 2026 ASCO Annual Meeting by 9 sources NCT04077463 · Janssen Research & Development, LLC DeepView → | advanced EGFR-mutant non-small cell lung cancer | Phase 1 | Deep | View | |||
| ANVIL nivolumab placed at 2026 ASCO Annual Meeting by 7 sources NCT02595944 · National Cancer Institute (NCI) DeepView → | resected stage IB-IIIA non-small cell lung cancer | Phase 3 | Deep | View | |||
| NEOVADE almonertinib plus adebrelimab plus carboplatin plus nab-paclitaxel placed at 2026 ASCO Annual Meeting by 5 sources NCT06300424 · Guangdong Provincial People's Hospital FocusedView → | II-IIIB EGFR-mutant NSCLC | Phase 2 | Focused | View | |||
| PAPILLON amivantamab placed at 2026 ASCO Annual Meeting by 3 sources NCT04538664 · Janssen Research & Development, LLC DeepView → | first-line EGFR exon 20 insertion-mutated advanced NSCLC | Phase 3 | Deep | View | |||
| ARCHER Drug not named yet placed at 2026 ASCO Annual Meeting by 2 sources NCT05950139 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins FocusedView → | advanced ALK+ NSCLC | Phase 1/Phase 2 | Focused | View | |||
| HARMONi ivonescimab placed at 2026 ASCO Annual Meeting by 2 sources NCT06396065 · Summit Therapeutics DeepView → | EGFR-mutant advanced non-squamous NSCLC after EGFR-TKI progression | Phase 3 | Deep | View | |||
| Ovarian cancer · 1 | |||||||
| ROSELLA relacorilant placed at 2026 ASCO Annual Meeting by 3 sources NCT05257408 · Corcept Therapeutics DeepView → | advanced platinum-resistant high-grade epithelial ovarian cancer | Phase 3 | Deep | View | |||
| Pancreatic cancer · 2 | |||||||
| RASolute 302 daraxonrasib (RMC-6236) placed at 2026 ASCO Annual Meeting by 167 sources NCT06625320 · Revolution Medicines, Inc. DeepView → | previously treated metastatic pancreatic ductal adenocarcinoma | Phase 3 | Deep | View | |||
| SWOG S2001 pembrolizumab plus olaparib placed at 2026 ASCO Annual Meeting by 2 sources NCT04548752 · National Cancer Institute (NCI) FocusedView → | metastatic pancreatic cancer with germline BRCA1/2 mutations | Phase 2 | Focused | View | |||
| Prostate cancer · 9 | |||||||
| TALAPRO-3 talazoparib plus enzalutamide placed at 2026 ASCO Annual Meeting by 31 sources NCT04821622 · Pfizer DeepView → | DDR gene-mutated metastatic castration-sensitive prostate cancer | Phase 3 | Deep | View | |||
| A-DREAM Tests a strategy, not a drug placed at 2026 ASCO Annual Meeting by 16 sources NCT05241860 · Alliance for Clinical Trials in Oncology DeepView → | metastatic hormone-sensitive prostate cancer | Phase 2 | Deep | View | |||
| ENZAMET enzalutamide placed at 2026 ASCO Annual Meeting by 10 sources NCT02446405 · University of Sydney DeepView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| ProstACT Global Drug not named yet placed at 2026 ASCO Annual Meeting by 3 sources NCT06520345 · Telix Pharmaceuticals (Innovations) Pty Limited DeepView → | PSMA-positive metastatic castration-resistant prostate cancer after ARPI | Phase 3 | Deep | View | |||
| PROTRACT enzalutamide; docetaxel placed at 2026 ASCO Annual Meeting by 3 sources NCT04015622 · British Columbia Cancer Agency FocusedView → | metastatic castration-resistant prostate cancer post abiraterone | Phase 2 | Focused | View | |||
| BNT324-03 BNT324 placed at 2026 ASCO Annual Meeting by 2 sources NCT07365995 · BioNTech SE FocusedView → | metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| BRCAAway olaparib plus abiraterone; olaparib placed at 2026 ASCO Annual Meeting by 2 sources NCT03012321 · Northwestern University DeepView → | metastatic castration-resistant prostate cancer with DNA repair defects | Phase 2 | Deep | View | |||
| ENZARAD enzalutamide placed at 2026 ASCO Annual Meeting by 2 sources NCT02446444 · University of Sydney DeepView → | high-risk clinically localised prostate cancer | Phase 3 | Deep | View | |||
| OMAHA-004 opevesostat placed at 2026 ASCO Annual Meeting by 2 sources NCT06136650 · Merck Sharp & Dohme LLC FocusedView → | metastatic castration-resistant prostate cancer post one NHA | Phase 3 | Focused | View | |||
| Renal cell carcinoma · 5 | |||||||
| RAMPART durvalumab; durvalumab plus tremelimumab placed at 2026 ASCO Annual Meeting by 15 sources NCT03288532 · University College, London DeepView → | intermediate- or high-risk resected renal cell carcinoma | Phase 3 | Deep | View | |||
| BioFront MO-03 placed at 2026 ASCO Annual Meeting by 3 sources NCT07383441 · SWOG Cancer Research Network DeepView → | advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-564 pembrolizumab placed at 2026 ASCO Annual Meeting by 3 sources NCT03142334 · Merck Sharp & Dohme LLC DeepView → | clear cell renal cell carcinoma post-nephrectomy | Phase 3 | Deep | View | |||
| PEAK-1 casdatifan plus cabozantinib placed at 2026 ASCO Annual Meeting by 2 sources NCT07011719 · Arcus Biosciences, Inc. DeepView → | advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| TiNivo-2 Drug not named yet placed at 2026 ASCO Annual Meeting by 2 sources NCT04987203 · AVEO Pharmaceuticals, Inc. DeepView → | renal cell carcinoma following an immune checkpoint inhibitor | Phase 3 | Deep | View | |||
| Small cell lung cancer · 1 | |||||||
| IMforte Drug not named yet placed at 2026 ASCO Annual Meeting by 3 sources NCT05091567 · Hoffmann-La Roche DeepView → | extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| Triple-negative breast cancer · 1 | |||||||
| PERSEVERE talazoparib plus pembrolizumab; inavolisib plus pembrolizumab placed at 2026 ASCO Annual Meeting by 4 sources NCT04849364 · Bryan Schneider, MD DeepView → | residual triple negative breast cancer | Phase 2 | Deep | View | |||
| Urothelial carcinoma · 8 | |||||||
| MAIN-CAV cabozantinib plus avelumab placed at 2026 ASCO Annual Meeting by 9 sources NCT05092958 · National Cancer Institute (NCI) DeepView → | metastatic urothelial cancer | Phase 3 | Deep | View | |||
| KEYNOTE-B15 enfortumab vedotin plus pembrolizumab placed at 2026 ASCO Annual Meeting by 8 sources NCT04700124 · Merck Sharp & Dohme LLC DeepView → | cisplatin-eligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| NEXUS-01 LY4052031; LY4052031 plus pembrolizumab placed at 2026 ASCO Annual Meeting by 8 sources NCT06465069 · Eli Lilly and Company DeepView → | advanced urothelial carcinoma or other solid tumors | Phase 1 | Deep | View | |||
| KEYNOTE-905 enfortumab vedotin plus pembrolizumab; pembrolizumab placed at 2026 ASCO Annual Meeting by 7 sources NCT03924895 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| SAKK 06/19 VPM1002BC plus atezolizumab plus cisplatin plus gemcitabine placed at 2026 ASCO Annual Meeting by 7 sources NCT04630730 · Swiss Cancer Institute DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| SURE-01 sacituzumab govitecan placed at 2026 ASCO Annual Meeting by 6 sources NCT05226117 · IRCCS San Raffaele DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| JAVELIN Bladder 100 avelumab placed at 2026 ASCO Annual Meeting by 3 sources NCT02603432 · Pfizer DeepView → | locally advanced or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| CheckMate 274 nivolumab placed at 2026 ASCO Annual Meeting by 2 sources NCT02632409 · Bristol-Myers Squibb DeepView → | high-risk invasive urothelial carcinoma | Phase 3 | Deep | View | |||
| Other · 5 | |||||||
| frontMIND tafasitamab plus lenalidomide placed at 2026 ASCO Annual Meeting by 9 sources NCT04824092 · Incyte Corporation DeepView → | newly diagnosed high-intermediate and high-risk DLBCL | Phase 3 | Deep | View | |||
| PUMP floxuridine placed at 2026 ASCO Annual Meeting by 3 sources NCT05863195 · ECOG-ACRIN Cancer Research Group DeepView → | unresectable colorectal liver metastases | Phase 3 | Deep | View | |||
| RINGSIDE varegacestat (AL102) placed at 2026 ASCO Annual Meeting by 3 sources NCT04871282 · Immunome, Inc. DeepView → | progressing desmoid tumors | Phase 2/Phase 3 | Deep | View | |||
| IMPACT2 Drug not named yet placed at 2026 ASCO Annual Meeting by 2 sources NCT02152254 · M.D. Anderson Cancer Center FocusedView → | metastatic cancer | Phase 2 | Focused | View | |||
| VEBrant vebreltinib placed at 2026 ASCO Annual Meeting by 2 sources NCT07153887 · Second Affiliated Hospital, Zhejiang University, School of Medicine FocusedView → | locally advanced or metastatic clear cell sarcoma | Phase 2 | Focused | View | |||